☆ 4.3 Review

Multimodal treatment of advanced renal cancer in 2017

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)

Journal

EXPERT REVIEW OF CLINICAL PHARMACOLOGY

Volume 10, Issue 12, Pages 1395-1402

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1080/17512433.2017.1386552

Keywords

Ablative therapies; cytoreductive nephrectomy; immunotherapy; metastasectomy; multidisciplinary care; radiotherapy; renal cell carcinoma; targeted therapy

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Introduction: in the last decades, the treatment of renal cell carcinoma has become more complex due to the introduction of novel systemic agents and the improvement of the loco-regional therapies that prolong survival maintaining a good quality of life.Areas covered: in this review, we summarize the currently available local and systemic treatment options, their indications and their hypothetical role in the management of advanced renal cell carcinoma, highlighting the need of multimodality treatment paradigms within interdisciplinary decision-making.Expert commentary: in early disease, radical or partial nephrectomy remains the standard of care, but innovative ablation techniques, including radiofrequency ablation, microwave ablation, cryoablation and so on, may represent an alternative option of treatment for small renal lesions in unfit patients who cannot undergo surgery. In metastatic setting, it is imperative a multidisciplinary team approach to select patients for a cytoreductive nephrectomy, metastasectomy, and/or systemic treatment, aiming to the optimization of the treatment strategy.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Hana Studentova, Martina Spisarova, Andrea Kopova, Anezka Zemankova, Bohuslav Melichar, Vladimir Student

Summary: Cytoreductive nephrectomy has long been considered the standard of care for patients with metastatic renal cell carcinoma. However, with the rapid changes in systemic therapy, the importance of this procedure has been widely discussed and disputed. Currently, there is a lack of prospective data on cytoreductive nephrectomy in the immunotherapy era, and retrospective studies with small patient numbers are the main source of evidence. Nevertheless, an individualized approach can help identify patients who may benefit from surgery combined with systemic treatment.

CANCERS (2023)

Add to Collection

Review Surgery

Ablative therapies versus partial nephrectomy for small renal masses-A systematic review and meta-analysis

Vinson Wai-Shun Chan, Ahmad Abul, Filzah Hanis Osman, Helen Hoi-Lam Ng, Kaiwen Wang, Yuhong Yuan, Jon Cartledge, Tze Min Wah

Summary: This review compared the oncological outcomes of ablative therapies (AT) and partial nephrectomy (PN) in patients with small renal masses (SRM). It found that while AT patients in the T1a group had worse overall survival, they experienced fewer post-operative complications, better kidney function preservation, and similar cancer-specific survival compared to PN patients. Further long-term high-quality studies are needed to confirm the potential benefits of AT, especially in T1b patients.

INTERNATIONAL JOURNAL OF SURGERY (2022)

Add to Collection

Review Oncology

New Paradigms for Cytoreductive Nephrectomy

Benjamin J. Lichtbroun, Arnav Srivastava, Sai Krishnaraya Doppalapudi, Kevin Chua, Eric A. Singer

Summary: This article discusses the role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) and the need to reevaluate its role with the emergence of immunotherapy agents. While current data suggests that CN may provide clinical benefit, further research is needed to clarify its role in this new era of cancer care.

CANCERS (2022)

Add to Collection

Article Urology & Nephrology

Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy

Stephen W. W. Reese, Sari Khaleel, Andrew Silagy, Amy Xie, Lennert Eismann, Katiana Vazquez-Rivera, Arnold Oparanozie, Sujata Patil, Jonathan Coleman, Robert Motzer, Ritesh R. R. Kotecha, Paul Russo, Martin H. H. Voss, A. Ari Hakimi

Summary: By evaluating the clinical course of patients placed on surveillance after cytoreductive nephrectomy, we found limited data to document their outcomes. Based on risk stratification using IMDC and number of metastatic sites, surveillance in favorable-risk patients can delay the initiation of systemic therapy, thereby delaying exposure to its side effects.

JOURNAL OF UROLOGY (2023)

Add to Collection

Review Oncology

Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review

Andre G. Gouveia, Dominic C. W. Chan, Peter J. Hoskin, Gustavo N. Marta, Fabio Trippa, Ernesto Maranzano, Edward Chow, Mauricio F. Silva

Summary: In patients with bone metastases, the utilization of radiotherapy faces challenges and uncertainties due to emerging treatment concepts such as oligometastases and local ablative therapies. Further research and refinement are needed to determine the optimal application of radiotherapy in complicated bone metastases.

RADIOTHERAPY AND ONCOLOGY (2021)

Add to Collection

Review Oncology

Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature

Giulia Mazzaschi, Federico Quaini, Melissa Bersanelli, Sebastiano Buti

Summary: The study found that in patients with metastatic renal cell carcinoma (mRCC), the majority (86.4%) underwent nephrectomy, and the trends of nephrectomy occurrence remained stable over the years. The evidence from randomized clinical trials and expanded access programs supports the clinical relevance of cytoreductive nephrectomy in mRCC patients receiving targeted- or immuno-therapy.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Article Surgery

Importance of Local Ablative Therapies for Lung Metastases in Patients With Colorectal Cancer

Byung Min Lee, Jee Suk Chang, Woong Sub Koom, Hwa Kyung Byun, Han Sang Kim, Seung-Hoon Beom, Caleb Oh, Young Joo Suh, Joong Bae Ahn, Sang Joon Shin, Byung Jo Park, Seong Yong Park

Summary: This study aimed to assess the effect of local ablative therapy (LAT) on overall survival in patients with lung metastases from colorectal cancer (CRC). The results showed that patients treated with LAT had significantly higher survival rates compared to those treated with systemic therapy alone.

ANNALS OF SURGERY (2023)

Add to Collection

Review Immunology

The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes

Kun-peng Li, Si-yu Chen, Chen-yang Wang, Xiao-ran Li, Li Yang

Summary: The purpose of this study was to evaluate the correlation between cytoreductive nephrectomy (CN) and outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immunotherapy. The results showed that CN was associated with superior overall survival (OS) in mRCC patients treated with immunotherapy.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Future prospects for mitosis-targeted antitumor therapies

Alfonso Serrano-del Valle, Chantal Reina-Ortiz, Andrea Benedi, Alberto Anel, Javier Naval, Isabel Marzo

Summary: Developing new therapies targeting cell cycle regulation and mitosis has shown potential, despite many being discontinued during clinical trials. Future efforts could focus on increasing cell death signals, targeting senescent cells, and promoting antitumor immune response to enhance the efficacy of these treatments.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma

Andrew W. Silagy, Ritesh R. Kotecha, Stanley Weng, Arturo Holmes, Nirmish Singla, Roy Mano, Kyrollis Attalla, Kate L. Weiss, Renzo G. DiNatale, Sujata Patil, Jonathan A. Coleman, Robert J. Motzer, Paul Russo, Martin H. Voss, A. Ari Hakimi

Summary: The systemic responses to cytoreductive nephrectomy in the management of metastatic renal cell carcinoma are variable. Patients undergoing surgery had fewer modifiable IMDC risk factors, fewer metastases, and higher proportions of clear cell histology. An increase in IMDC risk factors at 6 weeks and 6 months post-surgery was associated with adverse overall survival.

CANCER (2021)

Add to Collection

Article Oncology

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

Hanzhi Dong, Yuan Cao, Yan Jian, Jun Lei, Weimin Zhou, Xiaoling Yu, Xiquan Zhang, Zhiqiang Peng, Zhe Sun

Summary: This study analyzed the impact of nephrectomy on survival in patients with metastatic renal cell carcinoma who received immune-targeted therapy. The results showed that patients who underwent nephrectomy achieved survival benefits, and nephrectomy, clear cell carcinoma, and oligo-organ metastasis were found to be favorable independent prognostic factors.

BMC CANCER (2023)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma

X. -P. Shen, M. Xie, J. -S. Wang, X. Guo

Summary: This study compared the efficacy of immediate cytoreductive nephrectomy followed by PD-1 inhibitors with deferred nephrectomy after neoadjuvant therapy in metastatic renal cell carcinoma patients. The results showed that delaying nephrectomy and administering PD-1 inhibitors before debulking surgery significantly extended progression-free survival.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES (2023)

Add to Collection

Article Oncology

Stereotactic ablative radiotherapy for colorectal cancer liver metastasis

Hao Wang, Xuemin Li, Ran Peng, Yuxia Wang, Junjie Wang

Summary: SABR plays a crucial role in the multidisciplinary treatment of CRLM by causing an immunological change in the tumor microenvironment and potentially increasing the abscopal response rate of out-field lesions. The synergy of SABR and immunotherapy targets different steps of the immune-mediated response and may lead to a higher response rate by inducing cell death within and beyond the tumor sites.

SEMINARS IN CANCER BIOLOGY (2021)

Add to Collection

Review Surgery

Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis

Kun-peng Li, Miao He, Shun Wan, Si-yu Chen, Chen-yang Wang, Xiao-ran Li, Li Yang

Summary: This study compares the outcomes of patients with metastatic renal cell carcinoma who received presurgical systemic therapy followed by cytoreductive nephrectomy with those who underwent upfront nephrectomy followed by systemic therapy. The results demonstrate that cytoreductive nephrectomy after systemic therapy may be associated with improved overall survival in patients with metastatic renal cell carcinoma. However, no significant differences were found between the two groups in the immunotherapy-based combinations subgroup. Further research is needed to confirm these results.

INTERNATIONAL JOURNAL OF SURGERY (2023)

Add to Collection

Review Oncology

Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer

Tiuri E. Kroese, Peter S. N. van Rossum, Magnus Nilsson, Florian Lordick, Elizabeth C. Smyth, Riccardo Rosati, Philippe Nafteux, Domenico D'Ugo, M. Asif Chaudry, Wojciech Polkowkski, Franco Roviello, Ines Gockel, Piotr Kolodziejczyk, Karin Haustermans, Matthias Guckenberger, Marianne Nordsmark, Maria A. Hawkins, Andres Cervantes, Tania Fleitas, Eric van Cutsem, Markus Moehler, Anna D. Wagner, Hanneke W. M. van Laarhoven, Richard van Hillegersberg

Summary: Currently, there is a lack of uniform definition and treatment for oligometastatic esophagogastric cancer. The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to develop a multidisciplinary European consensus statement to improve outcomes for these patients.

EJSO (2023)

Add to Collection

Article Oncology

Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study

Paolo Manca, Salvatore Corallo, Sara Lonardi, Giovanni Fuca, Adele Busico, Alberto Giovanni Leone, Francesca Corti, Carlotta Antoniotti, Letizia Procaccio, Valeria Smiroldo, Margherita Ratti, Roberto Murialdo, Patrizia Racca, Filippo Pagani, Giovanni Randon, Antonia Martinetti, Elisa Sottotetti, Michele Prisciandaro, Margherita Ambrosini, Alessandra Raimondi, Federica Morano, Filippo Pietrantonio

Summary: Baseline ctDNA VAF can serve as a prognostic marker in patients with RAS wild-type mCRC, with high VAF associated with poorer overall survival. VAF outperformed traditional markers and remained significantly correlated with OS in a multivariate model.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Review Oncology

Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?

Margherita Ambrosini, Giovanni Fuca, Matteo Duca, Silvia Damian, Francesca De Santis, Francesca Corti, Sara Cresta, Filippo de Braud, Massimo Di Nicola

Summary: In the era of precision medicine, targeted protein degraders are emerging biological agents that can overcome treatment resistance and druggability limitations of certain key oncogenic proteins by promoting their specific degradation.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Article Oncology

Original Research Tumour mutational burden predicts resistance to EGFR/ BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer

Giovanni Randon, Rossana Intini, Chiara Cremolini, Elena Elez, Michael J. Overman, Jeeyun Lee, Paolo Manca, Francesca Bergamo, Filippo Pagani, Maria Antista, Valentina Angerilli, Francisco Javier Ros Montana, Daniele Lavacchi, Alessandra Boccaccino, Giovanni Fuca, Silvia Brich, Laura Cattaneo, Matteo Fassan, Filippo Pietrantonio, Sara Lonardi

Summary: This study aims to investigate the genomic and immunohistochemical expression profiles associated with primary resistance to EGFR/BRAF targeted therapy in patients with BRAF-mutated and microsatellite stable (MSS) metastatic colorectal cancer. The results suggest that the location of the tumor, genomic alterations, and gene expression patterns are associated with resistance to targeted therapy. Patients with a higher tumor mutational burden (TMB) have limited benefits from the treatment and may have worse prognosis.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study

Giovanni Fuca, Alessandra Raimondi, Michele Prisciandaro, Sara Lonardi, Chiara Cremolini, Margherita Ratti, Matteo Clavarezza, Roberto Murialdo, Andrea Sartore-Bianchi, Valeria Smiroldo, Rosa Berenato, Patrizia Racca, Francesca Bergamo, Salvatore Corallo, Maria Di Bartolomeo, Filippo de Braud, Federica Morano, Filippo Pietrantonio

Summary: This study evaluates the outcomes of anti-EGFR-based reinduction therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). The results suggest that there is no significant difference in treatment efficacy between anti-EGFR-based reinduction and any second line treatment. Factors such as early tumor shrinkage, deeper responses, and surgical treatment are associated with the use of anti-EGFR-based reinduction therapy.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Fasting- Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Claudio Vernieri, Giovanni Fuca, Francesca Ligorio, Veronica Huber, Andrea Vingiani, Fabio Iannelli, Alessandra Raimondi, Darawan Rinchai, Gianmaria Frige, Antonino Belfiore, Luca Lalli, Claudia Chiodoni, Valeria Cancila, Federica Zanardi, Arta Ajazi, Salvatore Cortellino, Viviana Vallacchi, Paola Squarcina, Agata Cova, Samantha Pesce, V Frati, Raghvendra Mall, Antonia Paola Corsetto, Angela Maria Rizzo, Cristina Ferraris, Secondo Folli, Marina Chiara Garassino, Giuseppe Capri, Giulia Bianchi, Mario Paolo Colombo, Saverio Minucci, Marco Foiani, Valter Daniel Longo, Giovanni Apolone, Valter Torri, Giancarlo Pruneri, Davide Bedogneti, Licia Rivoltini, Filippo de Braud

Summary: Cyclic fasting or fasting-mimicking diets (FMD) enhance antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. In a clinical trial, the five-day FMD was found to be safe and resulted in consistent decrease of blood glucose and growth factor concentration, recapitulating metabolic changes observed in preclinical experiments. The FMD also reshapes anticancer immunity and improves clinical outcomes in patients with cancer.

CANCER DISCOVERY (2022)

Add to Collection

Article Oncology

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer

Loic Reppel, Ourania Tsahouridis, Jason Akulian, Ian J. Davis, Hong Lee, Giovanni Fuca, Jared Weiss, Gianpietro Dotti, Chad Pecot, Barbara Savoldo

Summary: This study suggests that GD2 is a promising target for CAR-T cell therapy in lung cancer, and the use of tazemetostat can upregulate GD2 expression in tumor cells, enhancing their susceptibility to CAR-T cell targeting.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub- analysis of the NCT03340935 trial

Francesca Ligorio, Giovanni Fuca, Leonardo Provenzano, Riccardo Lobefaro, Lucrezia Zanenga, Andrea Vingiani, Antonino Belfiore, Alice Lorenzoni, Alessandra Alessi, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri

Summary: This study reports on several cases of advanced cancer patients achieving complete and long-lasting tumor remission through a combination of cyclic fasting-mimicking diets and standard anticancer therapies in the context of a clinical trial.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin

Emma Zattarin, Federico Nichetti, Francesca Ligorio, Laura Mazzeo, Riccardo Lobefaro, Giovanni Fuca, Giorgia Peverelli, Andrea Vingiani, Giulia Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri

Summary: Extramammary Paget disease (EMPD) is a rare form of skin cancer, with treatment options including surgery, radiotherapy, and chemotherapy. We report a case of HER2-overexpressing and AR-positive EMPD, which achieved tumor control with long-term treatment but showed no benefit from adding an AR blockade.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison

Riccardo Lobefaro, Luigi Mariani, Giorgia Peverelli, Francesca Ligorio, Giovanni Fuca, Alessandro Rametta, Emma Zattarin, Rita Leporati, Daniele Presti, Beatrice Cantarelli, Catherine Depretto, Andrea Vingiani, Siranoush Manoukian, Gianfranco Scaperrotta, Giulia V. Bianchi, Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri

Summary: Single-agent chemotherapy, alone or with immunotherapy, is the first-line standard-of-care treatment for advanced TNBC patients. This study supports the use of carboplatin-based doublets as first-line regimens and demonstrates better survival outcomes with carboplatin-gemcitabine in patients previously treated with taxanes. Further research is needed to investigate chemo-immunotherapy combinations containing carboplatin-based doublets.

CLINICAL BREAST CANCER (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini

Summary: The study aimed to investigate the effectiveness and tolerability of pembrolizumab-axitinib combination as a first-line treatment option for patients with chromophobe and papillary metastatic renal cell carcinoma (mRCC). The results showed that this combination therapy had a good response rate and tolerability in patients with chromophobe and papillary mRCC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial

Francesca Ligorio, Riccardo Lobefaro, Giovanni Fuca, Leonardo Provenzano, Lucrezia Zanenga, Vincenzo Nasca, Caterina Sposetti, Giulia Salvadori, Angela Ficchi, Andrea Franza, Antonia Martinetti, Elisa Sottotetti, Barbara Formisano, Catherine Depretto, Gianfranco Scaperrotta, Antonino Belfiore, Andrea Vingiani, Cristina Ferraris, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri

Summary: Severe calorie restriction in the form of cyclic fasting or fasting-mimicking diets enhances the antitumor activity of cytotoxic chemotherapy in mouse models of triple-negative breast cancer. Clinical evidence suggests that cyclic fasting-mimicking diets may have a positive impact on the outcomes of advanced triple-negative breast cancer patients.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchi, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, Giovanni Fuca

Summary: The study aims to test the prognostic ability of a novel inflammatory biomarker, the pan-immune-inflammation value (PIV), based on complete blood count (CBC), in patients with advanced triple-negative breast cancer (aNBC) who received first-line platinum-based chemotherapy. The results showed that PIV could serve as a prognostic factor and is associated with the efficacy of chemotherapy.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Giovanni Fuca, Mara Lecchi, Chiara Maura Ciniselli, Arianna Ottini, Andrea Spagnoletti, Laura Mazzeo, Daniele Morelli, Paola Frati, Martina Stroscia, Elisabella Ebrahem, Elisa Sottotetti, Giulia Galli, Maria Grazia D'Elia, Riccardo Lobefaro, Monika Ducceschi, Lorenza Di Guardo, Sherrie Bhoori, Salvatore Provenzano, Marco Platania, Monica Niger, Elena Colombo, Federico Nichetti, Matteo Duca, Licia Rivoltini, Roberta Mortarini, Paolo Baili, Giovanni Apolone, Filippo de Braud, Paolo Verderio, Silvia Damian

Summary: Systemic immunosuppression in cancer patients does not appear to significantly affect the cellular immune response to mRNA vaccines against SARS-CoV-2. However, further research is needed to investigate the interplay between immunotherapy and the longitudinal dynamics of immune response to mRNA vaccines in cancer patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Prognostic impact of body mass index (BMI) in HER2+breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications

Francesca Ligorio, Luca Zambelli, Giovanni Fuca, Riccardo Lobefaro, Marzia Santamaria, Emma Zattarin, Filippo de Braud, Claudio Vernieri

Summary: HER2+ breast cancer patients benefit from anti-HER2 therapy in terms of clinical outcomes. However, overweight and obesity may have a negative impact on the prognosis of early-stage HER2+ breast cancer patients, while a higher body mass index (BMI) may be associated with better clinical outcomes in advanced disease.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.